More Research Needed for Vitamin D's Cardiac Effect in PCI
Little effect on cardiac biomarker levels; significant effect on mean difference in CK-MB, hs-CRP
TUESDAY, Sept. 5, 2017 (HealthDay News) -- More research is needed to assess the role of vitamin D in the prevention of periprocedural myocardial injury, according to a study published online Aug. 25 in the Journal of Clinical Pharmacology.
Naser Aslanabadi, M.D., from Tabriz University of Medical Sciences in Iran, and colleagues randomized 99 patients admitted for elective percutaneous coronary intervention (PCI) into vitamin D (52 patients) and control (47 patients) groups. Twelve hours before PCI, the intervention group received 300,000 IU vitamin D orally.
The researchers found that 42 percent of patients in the control group and 34.6 percent in the intervention group had an increase in creatine kinase-MB (CK-MB) (P = 0.417). The increase in cardiac troponin I occurred in 8 percent of patients in the control group and 3.3 percent in the intervention group (P = 0419). There were no significant changes in the level of cardiac biomarkers. The mean difference in CK-MB between eight and 24 hours was significantly lower in the vitamin D group (P = 0.048). The vitamin D group also had significantly lower mean difference in high-sensitivity C-reactive protein (P = 0.045).
"This study could not show a clear effect of vitamin D in the prevention of cardiac injury during elective PCI," the authors write. "Based on the results of the present study, larger outcome-based, double-blind, placebo-controlled trials with a longer duration of vitamin D administration to correct the level of vitamin D above 30 ng/mL are recommended to demonstrate a clear effect of vitamin D supplementation in the prevention of cardiac injury following elective PCI."